Welcome!

News Feed Item

Viralytics $27 Million Transformational Capital Raising

SYDNEY, Jan. 30, 2014 /PRNewswire/ --

Highlights:

  • Transformational capital raising of up to $27.1m at $0.28 per share enabling Viralytics to complete 3 key CAVATAK™ clinical trials and to advance more rapidly to commercialisation
  • Viralytics to be fully funded until the end of 2016
  • Strengthens balance sheet ahead of potential commercial negotiations
  • Binding commitments to raise $23.0 million via two tranche placement. $6.1m via Tranche 1 (using Viralytics placement capacity) & $16.9m via Tranche 2 (Tranche 2 subject to shareholder approval )
  • Placement participants include leading US and UK-based specialist healthcare institutional investors
  • Up to another $4.1m to be raised from current shareholders via 1 for 6 non-renounceable entitlement offer
  • In the event of an entitlement offer shortfall, current shareholders also have the potential to buy additional shares at $0.28 via a "top-up facility" (see full details in the Entitlement Offer information booklet)

Viralytics Limited (ASX:VLA, OTCQX:VRACY) is undertaking a transformational capital raising of up to $27.1 million that is anticipated to fully fund the company to the end of 2016 including the completion of its key CAVATAKclinical trials.

It is anticipated that funds from the capital raising will enable the completion of the CAVATAKTM clinical trials program including:

  1. Phase 2 CALM trial of CAVATAKTM in late stage melanoma  patients
  2. Phase 1/2 STORM trial assessing the multiple intravenous dosing of CAVATAK™ in patients with solid tumours including melanoma, prostate, lung or metastatic bladder cancers due to commence in February 2014
  3. Randomised Phase 2 trial in melanoma patients planned for commencement late 2014[1]

Dr Malcolm McColl CEO said: "We have achieved major advances with CAVATAK™ in 2013 with excellent momentum entering 2014. This capital raising is transformational for the company as it introduces several high quality international institutional investors to the register for the first time.  We can now more rapidly advance the program and will be in a strong financial position to negotiate with pharmaceutical partners and optimise commercial outcomes."

"Support from leading specialist healthcare funds in the US and UK and small cap investors in Australia recognises the increasingly promising clinical trial outcomes achieved by the company in 2013 and validates the outstanding commercial potential of CAVATAK™, our oncolytic immunotherapy technology."

Bell Potter Securities Limited acted as the Lead Manager to the capital raising with Roth Capital Partners acting as the Sole US Placement Agent.

Offer Details:

The Placement and the Entitlement Offer price of $0.28 represents a 12.5% discount to the weighted average closing price for the fifteen trading days to 24 January 2014 (being the last trading day before the capital raising was announced by the company).

The Placement comprises two Tranches.

  1. Tranche 1 is a $6.1 million placement to professional and sophisticated investors using Viralytics' existing placement capacity under the ASX Listing Rules (First Tranche Placement);
  2. Tranche 2 is a $16.9 million placement to professional and sophisticated investors and is subject to shareholder approval (Second Tranche Placement). A shareholder meeting is expected to be held on or around 6 March 2014.

Shares issued under the Placement and the Entitlement Offer will rank equally with existing shares.  However, participants in the Placement will not be eligible to participate in the Entitlement Offer.

Under the Entitlement Offer, eligible shareholders will be able to subscribe for 1 new ordinary share in Viralytics for every 6 existing shares held at 7.00 pm (AEDT) on Friday, 7 February 2014 (Record Date) at the offer price (Entitlements).  

The Entitlements are non-renounceable and will not be tradeable on ASX or otherwise transferable. Shareholders who do not take up their Entitlements will not receive any value in respect of those Entitlements that they do not take up. 

The Entitlement Offer will include a top-up facility under which eligible shareholders who take up their full Entitlement will be invited to apply for additional shares in the Entitlement Offer from a pool of those not taken up by other eligible shareholders. There is no guarantee that applicants under this top-up facility will receive all or any of the shares they apply for under the facility. The Board of Viralytics reserves the right to allocate the top-up facility at its discretion. 

Viralytics will notify shareholders as to whether they are eligible to participate in the Entitlement Offer.  Eligible shareholders will receive an information booklet including a personalised entitlement and acceptance form that will provide further details of how to participate in the Entitlement Offer.

Also, under ASX Listing Rules, Appendix 7A, Viralytics will despatch a letter in relation to the Entitlement Offer to each holder of options to subscribe for Viralytics shares.

A presentation on the Entitlement Offer has been lodged with ASX today and can be downloaded from ASX's website, http://www.asx.com.au .

Offer Timetable[2]

Activity

Date

Announcement of the Entitlement Offer

30 January 2014

Mailing of the Entitlement Offer details

31 January 2014

Ex date

3 February 2014

Record Date for Entitlement Offer (7.00pm (AEDT))

7 February 2014

Information booklet and entitlement and acceptance form despatched

11 February 2014

Entitlement Offer opens

11 February 2014

Closing date for acceptances under Entitlement Offer (5.00pm (AEDT))

25 February 2014

New Shares quoted on deferred settlement basis

26 February 2014

Company notifies ASX of under subscriptions

28 February 2014

Allotment of New Shares under the Entitlement Offer

5 March 2014

Despatch of holding statements for New Shares issued under the Entitlement Offer

6 March 2014

Normal ASX trading for New Shares issued under the Entitlement Offer commences

6 March 2014

Anticipated date for general meeting of shareholders to ratify the First Tranche Placement and approve the Second Tranche Placement

6 March 2014

Anticipated date for settlement of Second Tranche Placement

11 March 2014

Shareholder Enquiries

The Offer information line will be open on 11 February 2014, when the information booklets and acceptance forms are despatched:

Australian Shareholders: 1800 645 237

New Zealand Shareholders:  +61-2-8280-7585

Notes:

[1] Details of Viralytics' objectives, relevant assumptions and risks are contained in the Entitlement Offer information booklet and investor presentation also released today.

[2] All dates are indicative only and subject to change. Viralytics reserves the right to withdraw or vary the timetable without notice.

* All the currency figures mentioned above are Australian dollars.

Important Information
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the 'US Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative thereof or comparable terminology. Any forecasts or other forward looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. Viralytics does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.

About Viralytics Ltd:
Viralytics is developing oncolytic virotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma.  CAVATAK™ acts to kill both local and metastatic cancer cells, by direct cytolysis and a possible immune response. The preferential targeting of cancer rather than healthy cells provides the potential for low toxicity in the patient. The company has completed enrolling a phase II clinical trial, of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. Viralytics plans to commence a Phase I/II trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. Viralytics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency and will commence the STORM trial at three prominent UK sites in early 2014.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.

Enquiries:

Dr Malcolm McColl
Chief Executive Officer
+61-2-9988-4000

Mr Rudi Michelson
Monsoon Communications
+61-3-9620-3333

SOURCE Viralytics Limited

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DX World EXPO, LLC, a Lighthouse Point, Florida-based startup trade show producer and the creator of "DXWorldEXPO® - Digital Transformation Conference & Expo" has announced its executive management team. The team is headed by Levent Selamoglu, who has been named CEO. "Now is the time for a truly global DX event, to bring together the leading minds from the technology world in a conversation about Digital Transformation," he said in making the announcement.
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Conference Guru has been named “Media Sponsor” of the 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. A valuable conference experience generates new contacts, sales leads, potential strategic partners and potential investors; helps gather competitive intelligence and even provides inspiration for new products and services. Conference Guru works with conference organizers to pass great deals to gre...
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develop...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
"ZeroStack is a startup in Silicon Valley. We're solving a very interesting problem around bringing public cloud convenience with private cloud control for enterprises and mid-size companies," explained Kamesh Pemmaraju, VP of Product Management at ZeroStack, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...